MPCUK

Mark Middleton, MD, PhD, FRCP is Professor of Experimental Cancer Medicine at the University of Oxford and a Medical Oncologist at the Oxford Cancer Centre. He directs the Early Phase Clinical Trials Unit in Oxford and is Lead Clinician for Cancer Services at the Oxford University Hospitals.

Professor Middleton graduated from Gonville and Caius College, Cambridge and New College, Oxford. He trained in oncology at the Christie Hospital and undertook his PhD in the field of therapeutic resistance at the Paterson Institute for Cancer Research, Manchester.

His clinical interests are in drug development and the treatment of melanoma. His research work focuses on the genetic characterisation of patients and their melanoma and on the mechanisms underpinning successful anti-angiogenic and immune therapies. Mark has been Chief or Principal Investigator on over 50 melanoma and 50 phase 1 trials and has been closely involved in the clinical development of several new therapies including DNA repair inhibitors, MEK inhibitors, immune checkpoint inhibitors and ImmTACs.